AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22848508 — intervention group
Group type: EXPERIMENTAL
Intervention: Group x DRD2/ANKK1‐TaqIA A1‐allele status interaction
Number of subjects: 84
Study 22848508 — intervention group
Group type: EXPERIMENTAL
Intervention: Group x DRD4 7R-allele status interaction
Number of subjects: 84
Study 18684666 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier use
Number of subjects: 24
Study 18684666 — intervention group
Group type: COMPARATOR
Intervention: Control (non-users)
Number of subjects: 24
Study 16968813 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 0
Study 16968813 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 16968813 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Pioglitazone and Metformin
Number of subjects: 0
Study 15030987 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 months combination therapy with interferon (3MU tiw) and ribavirin (1000-1200 mg/day)
Number of subjects: 300
Study 15030987 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months combination therapy with interferon and ribavirin
Number of subjects: 300
Study 15030987 — intervention group
Group type: COMPARATOR
Intervention: 18 months interferon combined with placebo
Number of subjects: 300
Study 12383038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 0
Study 12383038 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 12383038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 12383038 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg/day)
Number of subjects: 0
Study 9661572 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. fluconazole 400 mg
Number of subjects: 9
Study 9661572 — intervention group
Group type: EXPERIMENTAL
Intervention: oral fluconazole 400 mg
Number of subjects: 9
Study 9661572 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 7663917 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder symptoms reported by teenagers at age 17
Number of subjects: 736
Study 7663917 — intervention group
Group type: EXPERIMENTAL
Intervention: General decrease in frequency and intensity of symptoms from age 7 to 17
Number of subjects: 736
Study 7663917 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire for medical help regarding micturition disturbances
Number of subjects: 736
Study 2528925 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil-nitrous oxide/oxygen anesthesia (S group)
Number of subjects: 44
Study 2528925 — intervention group
Group type: COMPARATOR
Intervention: Halothane-nitrous oxide/oxygen anesthesia (H group)
Number of subjects: 44
Study 2528925 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (S and H)
Number of subjects: 44
Study 4596632 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulphate administered for six weeks
Number of subjects: 65
Study 4596632 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (two groups)
Number of subjects: 65
Study 4596632 — intervention group
Group type: COMPARATOR
Intervention: Patients with bronchial carcinoma
Number of subjects: 65
Study 31124381 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol tablet 60,000 IU per week for 8 weeks
Number of subjects: 72
Study 31124381 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 72
Study 30868576 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU‐based preoperative chemoradiotherapy (CRT) alone or with oxaliplatin
Number of subjects: 1236
Study 30868576 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU‐based preoperative chemoradiotherapy (CRT) with oxaliplatin
Number of subjects: 1236
Study 28867602 — intervention group
Group type: EXPERIMENTAL
Intervention: Secnidazole 2 g
Number of subjects: 189
Study 28867602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study 25082957 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training
Number of subjects: 66
Study 25082957 — intervention group
Group type: COMPARATOR
Intervention: Balance training
Number of subjects: 66
Study 22483625 — intervention group
Group type: EXPERIMENTAL
Intervention: Early repolarization (ER) ≥ 0.1 mV in inferior and/or lateral leads
Number of subjects: 281
Study 22483625 — intervention group
Group type: EXPERIMENTAL
Intervention: ER ≥ 0.1 mV and horizontal/descending ST variant (n=18)
Number of subjects: 281
Study 22483625 — intervention group
Group type: EXPERIMENTAL
Intervention: ER in inferior leads and horizontal/descending ST-segment variant
Number of subjects: 281
Study 22483625 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascending ST variant
Number of subjects: 281
Study 21557440 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 470
Study 21557440 — intervention group
Group type: COMPARATOR
Intervention: Neutral protamine hagedorn insulin
Number of subjects: 470
Study 18664708 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback training
Number of subjects: 0
Study 18664708 — intervention group
Group type: EXPERIMENTAL
Intervention: Familiarization training
Number of subjects: 0
Study 18664708 — intervention group
Group type: COMPARATOR
Intervention: No training (Control group)
Number of subjects: 0
Study 16687897 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial resuscitation, appropriate antimicrobial treatment, selection of optimal control methods, properties of fluid therapy, use of vasopressors and inotropic therapy, proper corticosteroid administration, use of recombinant human activated protein C, glucose control
Number of subjects: 0
Study 15273640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavit
Number of subjects: 45
Study 15273640 — intervention group
Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 45
Study 15273640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultratemp Firm
Number of subjects: 45
Study 15273640 — intervention group
Group type: COMPARATOR
Intervention: Negative Control (no restorative material, coated with sticky wax)
Number of subjects: 45
Study 15273640 — intervention group
Group type: COMPARATOR
Intervention: Positive Control (no restorative material, no sticky wax)
Number of subjects: 45
Study 11677930 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 375 micrograms s.c.
Number of subjects: 0
Study 11677930 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 750 micrograms s.c.
Number of subjects: 0
Study 11677930 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 375 micrograms i.v.
Number of subjects: 0
Study 11677930 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim 750 micrograms i.v.
Number of subjects: 0
Study 9206387 — intervention group
Group type: EXPERIMENTAL
Intervention: ALL-BOND 2
Number of subjects: 10
Study 9206387 — intervention group
Group type: COMPARATOR
Intervention: Butler Protect
Number of subjects: 10
Study 7961011 — intervention group
Group type: COMPARATOR
Intervention: Brachytherapy alone (18 patients)
Number of subjects: 361
Study 7961011 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam irradiation + brachytherapy (343 patients)
Number of subjects: 361
Study 7961011 — intervention group
Group type: COMPARATOR
Intervention: T1T2 tumors (compared to T3)
Number of subjects: 361
Study 7961011 — intervention group
Group type: COMPARATOR
Intervention: N0 tumors (compared to N+)
Number of subjects: 361
Study 7961011 — intervention group
Group type: COMPARATOR
Intervention: Tumors with extension to the mobile tongue or base
Number of subjects: 361
Study 7961011 — intervention group
Group type: COMPARATOR
Intervention: Total duration of treatment < 55 days
Number of subjects: 361
Study 7961011 — intervention group
Group type: COMPARATOR
Intervention: Number of days between External Beam Irradiation and brachytherapy < 20
Number of subjects: 361
Study 7961011 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose rate
Number of subjects: 361
Study 3617198 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron dextran prophylaxis
Number of subjects: 0
Study 3617198 — intervention group
Group type: COMPARATOR
Intervention: Normal or heterozygote groups
Number of subjects: 0
Study 30093519 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic-assisted balloon tibioplasty
Number of subjects: 80
Study 30093519 — intervention group
Group type: COMPARATOR
Intervention: Open reduction internal fixation (ORIF)
Number of subjects: 80
Study 26683985 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent education brochure plus a student curriculum on the four recommended vaccines
Number of subjects: 686
Study 26683985 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 686
Study 26683985 — intervention group
Group type: COMPARATOR
Intervention: Parent education brochure
Number of subjects: 686
Study 25530341 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 56
Study 25530341 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (15 minutes bicycling at 75% VO2max)
Number of subjects: 56
Study 25530341 — intervention group
Group type: COMPARATOR
Intervention: Control session (15 minutes quiet rest)
Number of subjects: 56
Study 23873291 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 1055
Study 23873291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1055
Study 20960101 — intervention group
Group type: EXPERIMENTAL
Intervention: Glulisine
Number of subjects: 20
Study 20960101 — intervention group
Group type: COMPARATOR
Intervention: Lispro
Number of subjects: 20
Study 19731862 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (administered to group A)
Number of subjects: 0
Study 19731862 — intervention group
Group type: COMPARATOR
Intervention: No antimycotics (control group B)
Number of subjects: 0
Study 16353228 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonographically guided steroid injection (7 mg betamethasone and 0.5 ml of 1% lidocaine)
Number of subjects: 25
Study 16353228 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation-guided steroid injection (7 mg betamethasone and 0.5 ml of 1% lidocaine)
Number of subjects: 25
Study 14573329 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg caffeine
Number of subjects: 20
Study 14573329 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 10911415 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of cast immobilization
Number of subjects: 10
Study 10911415 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weeks of supervised physical therapy
Number of subjects: 10
Study 10911415 — intervention group
Group type: COMPARATOR
Intervention: Control group (noninjured comparison subjects)
Number of subjects: 10
Study 10911415 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar-flexor peak torque
Number of subjects: 10
Study 8864313 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg racemic ketoprofen
Number of subjects: 7
Study 8864313 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg racemic ketoprofen
Number of subjects: 7
Study 1551350 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginic acid-antacid (extra-strength Gaviscon)
Number of subjects: 10
Study 1551350 — intervention group
Group type: COMPARATOR
Intervention: Control antacid (equal acid-neutralizing capacity)
Number of subjects: 10
Study 3158272 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 370
Study 3158272 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim-sulfamethoxazole
Number of subjects: 370
Study 30584459 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich herbal congee (D2 group, 1500 mg/day)
Number of subjects: 45
Study 30584459 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich herbal congee (D1 group, 50 mg/day)
Number of subjects: 45
Study 30584459 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 45
Study 27662495 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment for 10 minutes at GV 26, Ex-HN 3, bilateral LI 4, and ST 36
Number of subjects: 14
Study 27662495 — intervention group
Group type: COMPARATOR
Intervention: Control session without acupuncture
Number of subjects: 14
Study 27662495 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 14
Study 24669147 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification (Group 1)
Number of subjects: 200
Study 24669147 — intervention group
Group type: COMPARATOR
Intervention: Manual Small-Incision Cataract Surgery (MSICS) (Group 2)
Number of subjects: 200
Study 22004355 — intervention group
Group type: EXPERIMENTAL
Intervention: Drain inserted
Number of subjects: 272
Study 22004355 — intervention group
Group type: COMPARATOR
Intervention: No drain
Number of subjects: 272
Study 20720415 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 509
Study 20720415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509
Study 18359648 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy-lifestyle (HL)
Number of subjects: 193
Study 18359648 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (D)
Number of subjects: 193
Study 18359648 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (E)
Number of subjects: 193
Study 18359648 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus Exercise (D+E)
Number of subjects: 193
Study 18359648 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention groups combined
Number of subjects: 193
Study 15950847 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydroxyethyl starch (HES) 6% 200,000/0.5, 500 mL
Number of subjects: 40
Study 15950847 — intervention group
Group type: COMPARATOR
Intervention: Electrolyte solution, 500 mL
Number of subjects: 40
Study 12390336 — intervention group
Group type: EXPERIMENTAL
Intervention: High-level TSH suppression (0.4-0.6 mIU/ml)
Number of subjects: 49
Study 12390336 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level TSH suppression (< or = 0.01 mIU/ml)
Number of subjects: 49
Study 12390336 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 49
Study 10563539 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular paper-filtered coffee (280 ml)
Number of subjects: 15
Study 10563539 — intervention group
Group type: COMPARATOR
Intervention: Warm water (280 ml)
Number of subjects: 15
Study 7671515 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary reamed intramedullary nailing
Number of subjects: 42
Study 7671515 — intervention group
Group type: COMPARATOR
Intervention: Delayed reamed intramedullary nailing
Number of subjects: 42
Study 2130173 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage palatal closure (Unil-T) with primary veloplasty at 20 months and hard palate closure at 5 years 10 months
Number of subjects: 45
Study 2130173 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage mucoperiosteal palatal push-back procedure (Unil-S)
Number of subjects: 45
Study 2130173 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-stage palatal closure (Bil-S)
Number of subjects: 45
Study 2130173 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage palatal closure (Bil-T)
Number of subjects: 45
Study 2130173 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-cleft subjects)
Number of subjects: 45
Study 293922 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 8
Study 293922 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 8
Study 31068654 — intervention group
Group type: EXPERIMENTAL
Intervention: tRNS (1.5 mA, 100-500 Hz)
Number of subjects: 30
Study 31068654 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 30
Study 27435518 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaborated inoculation
Number of subjects: 340
Study 27435518 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited inoculation
Number of subjects: 340
Study 26012232 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic injected both SC and deep (GB)
Number of subjects: 60
Study 26012232 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic injected subcutaneous (GA)
Number of subjects: 60
Study 26012232 — intervention group
Group type: COMPARATOR
Intervention: Saline subcutaneous & deep (GC)
Number of subjects: 60
Study 23378325 — intervention group
Group type: EXPERIMENTAL
Intervention: IM IFNβ‐1a
Number of subjects: 136
Study 23378325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 21429817 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and zinc tolerance test before surgery
Number of subjects: 9
Study 21429817 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and zinc tolerance test after surgery
Number of subjects: 9
Study 21429817 — intervention group
Group type: COMPARATOR
Intervention: Iron and zinc tolerance test before and after surgery
Number of subjects: 9
Study 19153001 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (80 mg in 50 ml of saline) intravesically within 24 h of TUR
Number of subjects: 305
Study 19153001 — intervention group
Group type: COMPARATOR
Intervention: No treatment after TUR
Number of subjects: 305
Study 17578314 — intervention group
Group type: EXPERIMENTAL
Intervention: Pingchuan Yiqi Granule (PYG)
Number of subjects: 80
Study 17578314 — intervention group
Group type: COMPARATOR
Intervention: Ruyi Dingchuan Pill (RDP)
Number of subjects: 80
Study 11004346 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary estriol (E3) test at or above 2.1 ng/mL
Number of subjects: 956
Study 11004346 — intervention group
Group type: EXPERIMENTAL
Intervention: Two consecutive positive salivary E3 tests
Number of subjects: 956
Study 11004346 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary E3 test at or above 1.4 ng/mL
Number of subjects: 956
Study 8988071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine plus caffeine (20 mg ephedrine plus 200 mg caffeine three times a day)
Number of subjects: 225
Study 8988071 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 225
Study 8988071 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine plus caffeine
Number of subjects: 225
Study 8988071 — intervention group
Group type: COMPARATOR
Intervention: Ephedrine plus caffeine and Placebo
Number of subjects: 225
Study 1730189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime 1 g every 8 hr
Number of subjects: 74
Study 1730189 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone 1 g every 12 hr
Number of subjects: 74
Study 6143505 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg sublingually, followed by 10 mg every 6 hours for a total of 24 hours)
Number of subjects: 26
Study 6143505 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 26
Study 31460669 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent opioids with benzodiazepines or nonbenzodiazepine sedatives (BZD-S)
Number of subjects: 1500
Study 31460669 — intervention group
Group type: COMPARATOR
Intervention: Opioids-only group
Number of subjects: 1500
Study 30518044 — intervention group
Group type: EXPERIMENTAL
Intervention: NU-AGE diet group (dietary intervention for one year including 15 food groups and vitamin D supplement)
Number of subjects: 1296
Study 30518044 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1296
Study 27687032 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine-QR (B-QR)
Number of subjects: 1791
Study 27687032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1791
Study 24906074 — intervention group
Group type: EXPERIMENTAL
Intervention: Ground monitoring measurements and satellite aerosol optical depth (AOD) data
Number of subjects: 0
Study 24906074 — intervention group
Group type: EXPERIMENTAL
Intervention: Speciation data analysis
Number of subjects: 0
Study 22424012 — intervention group
Group type: EXPERIMENTAL
Intervention: Transendocardial injection of autologous aldehyde dehydrogenase-bright (ALDH(br)) cells
Number of subjects: 20
Study 22424012 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ALDH(br) cells)
Number of subjects: 20
Study 20142410 — intervention group
Group type: COMPARATOR
Intervention: One course of adjuvant CVB chemotherapy for VASC- patients
Number of subjects: 232
Study 20142410 — intervention group
Group type: EXPERIMENTAL
Intervention: Two courses of adjuvant CVB chemotherapy for VASC+ patients
Number of subjects: 232
Study 20142410 — intervention group
Group type: COMPARATOR
Intervention: Surveillance for VASC- patients
Number of subjects: 232
Study 20142410 — intervention group
Group type: COMPARATOR
Intervention: Surveillance for VASC+ patients
Number of subjects: 232
Study 20142410 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant CVB chemotherapy (both groups)
Number of subjects: 232
Study 19020146 — intervention group
Group type: EXPERIMENTAL
Intervention: Demand-only PCEA (5 mL bolus, 15 min lockout interval)
Number of subjects: 300
Study 19020146 — intervention group
Group type: COMPARATOR
Intervention: PCEA with background infusion (5 mL/h, 5 mL bolus, 12 min lockout interval)
Number of subjects: 300
Study 19020146 — intervention group
Group type: COMPARATOR
Intervention: PCEA with background infusion (10 mL/h, 5 mL bolus, 10 min lockout interval)
Number of subjects: 300
Study 15840760 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 123
Study 15840760 — intervention group
Group type: COMPARATOR
Intervention: Conventional Method of Care (CMC)
Number of subjects: 123
Study 15840760 — intervention group
Group type: EXPERIMENTAL
Intervention: KMC
Number of subjects: 123
Study 15840760 — intervention group
Group type: COMPARATOR
Intervention: CMC
Number of subjects: 123
Study 12432809 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic spinal fixation system
Number of subjects: 155
Study 10421228 — intervention group
Group type: EXPERIMENTAL
Intervention: TFA diet (5.1 E% trans fatty acids)
Number of subjects: 14
Study 10421228 — intervention group
Group type: COMPARATOR
Intervention: MUFA diet (5.2 E% oleic acid)
Number of subjects: 14
Study 7493430 — intervention group
Group type: EXPERIMENTAL
Intervention: Biosynthetic human growth hormone, subcutaneously, daily dose of 0.02-0.05 i.u./kg at bedtime
Number of subjects: 40
Study 7493430 — intervention group
Group type: COMPARATOR
Intervention: Control subjects with normal glucose tolerance
Number of subjects: 40
Study 7493430 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypopituitary patients with impaired glucose tolerance
Number of subjects: 40